| Description | This product is a human monoclonal antibody that reacts with Respiratory Syncytial Virus F glycoprotein. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Respiratory Syncytial Virus |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | DB; IF; IP; Neut; FuncS; ELISA; FC; WB |
| Application Notes | The antibody is recommended for detection of Respiratory Syncytial Virus F glycoprotein by IF, IP, Neut, FuncS, ELISA, FC, WB assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | Respiratory Syncytial Virus F glycoprotein |
| Alternative Name | Respiratory Syncytial Virus F; Respiratory Syncytial Virus F protein |
| Research Area | Infectious Disease |
Figure 1 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in WB
Western blot analysis of V3S-0622-YC5270 was performed by loading Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC5270 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reduced antigen (1 μg)
Figure 1 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in WB
Figure 2 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in DB
Dot Blot analysis of V3S-0622-YC5270 was performed by coating with Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (His Tag).
V3S-0622-YC5270 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 2 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in DB
Figure 3 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in ELISA
ELISA analysis of V3S-0622-YC5270 was performed by coating with Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (His Tag). Then blocked with BSA, and incubated with V3S-0622-YC5270. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-RSV glycoprotein F Monoclonal Antibody (V3S-0622-YC5270) in ELISA
